The Effect of Garlic Tablet on Borderline Gestational Diabetes Mellitus

The Effect of Garlic Tablet on Borderline Gestational Diabetes Mellitus: a Randomized Controlled Trial

Status

Active, not recruiting

Phases

Unknown

Study type

Interventional

Source

IRCT

Registry ID

IRCT201509193706N27

Enrollment

Registered

2015-10-27

Start date

2015-10-24

Completion date

Unknown

Last updated

2018-02-22

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Borderline Gestational Diabetes Mellitus. Other specified diseases and conditions complicating pregnancy, childbirth and the puerperium

Interventions

Intervention 1: the control group: one placebo tablet daily containing 400 mg of powdered starch, for 8 weeks. Intervention 2: The intervention group: one garlic tablet (400 mg) daily for 8 weeks

produced by Amin pharmaceutical co.

Treatment - Drugs

the control group: one placebo tablet daily containing 400 mg of powdered starch, for 8 weeks

The intervention group: one garlic tablet (400 mg) daily for 8 weeks

Eligibility

Sex/Gender

Female

Age

15 Years to 49 Years

Inclusion criteria

Inclusion criteria: Inclusion criteria: single pregnancy and healthy fetus (based on sonography), gestational age of 24 to 28 weeks, FBS between 93 to 125 mg/dL and normal oral 75-gram glucose tolerance test (one hour glucose<180 mg/dl and two hours<153 mg/dl). Exclusion criteria: history of gestational diabetes or hypertension, chronic conditions such as liver, stomach, ... diseases, having allergic to garlic, no access to phone line for follow-up, participation in other trials.

Exclusion criteria

Exclusion criteria:

Design outcomes

Primary

Measure	Time frame
Fasting blood glucose. Timepoint: Before the intervention, 4 and 8 weeks after intervention. Method of measurement: labratory assessment.	—

Secondary

Measure	Time frame
Incidence of preeclampsia. Timepoint: 4 and 8 weeks after intervention. Method of measurement: clinical (blood pressure & Edema) & labratory (proteinuria) assessment.;Type of delivery. Timepoint: After delivery. Method of measurement: Via calling.;Bith weight. Timepoint: at birth. Method of measurement: Recorded in infant growth monitoring card.;Birth Hight. Timepoint: At birth. Method of measurement: Based on record on neonatal health card.;Side event. Timepoint: during 8 weeks after starting intervention. Method of measurement: Self- report on a dairy.;Woman satisfaction of the intervention. Timepoint: 4 and 8 weeks after intervention. Method of measurement: self- report.	—

Measure

Time frame

Incidence of preeclampsia. Timepoint: 4 and 8 weeks after intervention. Method of measurement: clinical (blood pressure & Edema) & labratory (proteinuria) assessment.;Type of delivery. Timepoint: After delivery. Method of measurement: Via calling.;Bith weight. Timepoint: at birth. Method of measurement: Recorded in infant growth monitoring card.;Birth Hight. Timepoint: At birth. Method of measurement: Based on record on neonatal health card.;Side event. Timepoint: during 8 weeks after starting intervention. Method of measurement: Self- report on a dairy.;Woman satisfaction of the intervention. Timepoint: 4 and 8 weeks after intervention. Method of measurement: self- report.

—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactFaroughi Farnaz

Nursing & Midwifery Faculty, Tabriz University of Medical Sciences,

Faroughifarnaz.m@gmail.com+98 41 3444 1869

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026